FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322703295> ?p ?o ?g. }

• W4322703295 endingPage "1362" @default.
• W4322703295 startingPage "1353" @default.
• W4322703295 abstract "BackgroundLymphopenia is a predictive factor for hematological toxicity, progression and early death in advanced cancers including metastatic breast cancer (MBC). CYT107 is a recombinant interleukin 7 (IL-7) (Cytheris, now Revimmune), well tolerated and able to expand lymphocyte pool in humans. The aims of this study were to determine the optimal schedule to deliver CYT107 and to assess its effect on clinical end points.Patient and methodsThis placebo-controlled, double blind, phase IIa was conducted in MBC patients with <1500/µl lymphocytes treated with capecitabine. Using a 2-by-2 factorial design, 20 patients were randomly allocated to four arms to receive (i) before chemotherapy: CYT107 or placebo; then (ii) during chemotherapy: CYT107 or placebo. The primary end point was CD4+ count changes before and during chemotherapy. Secondary end points were hematological toxicity, safety, overall response, progression-free survival (PFS) and overall survival (OS). Quantification and functional competence of circulating immune cells were also assessed.ResultsWhen administered before chemotherapy, CYT107 induced a significant increase of CD4+ [+148.1% in CYT107 versus +9.9% in placebo groups, (Wilcoxon, P = 0.002)] and CD8+ T-cell counts, including both naïve and memory subsets. When CYT107 was administered during chemotherapy, the magnitude of CD4+ and CD8+ increase was less important. No modulation of immune cell functional competence was observed. CYT107 was well tolerated with no related ≥grade 3 adverse events except 1 fatal suspected unexpected serious adverse reaction (SUSAR) of uncertain relationship. Of the 12 cases evaluable for response, 6 of 7 patients (86%) receiving CYT107 before chemotherapy achieved a response or stabilization, whereas two of five patients (40%) receiving placebo achieved the same result. No significant difference was observed for PFS or OS.ConclusionIn lymphopenic MBC, CYT107 increases CD4+ and other T-cell subset counts without altering their function. A larger clinical trial to demonstrate its impact on clinical outcome is warranted.ClinicalTrials.gov IdentifierNCT01362107." @default.
• W4322703295 created "2023-03-02" @default.
• W4322703295 creator A5006675365 @default.
• W4322703295 creator A5008727148 @default.
• W4322703295 creator A5009371827 @default.
• W4322703295 creator A5019588141 @default.
• W4322703295 creator A5020024953 @default.
• W4322703295 creator A5020487290 @default.
• W4322703295 creator A5022848420 @default.
• W4322703295 creator A5024404992 @default.
• W4322703295 creator A5025761056 @default.
• W4322703295 creator A5025970784 @default.
• W4322703295 creator A5027371764 @default.
• W4322703295 creator A5034604079 @default.
• W4322703295 creator A5036405779 @default.
• W4322703295 creator A5038384830 @default.
• W4322703295 creator A5041410352 @default.
• W4322703295 creator A5042202815 @default.
• W4322703295 creator A5043554288 @default.
• W4322703295 creator A5048784388 @default.
• W4322703295 creator A5063289374 @default.
• W4322703295 creator A5065321807 @default.
• W4322703295 creator A5073434591 @default.
• W4322703295 creator A5073713547 @default.
• W4322703295 creator A5083175355 @default.
• W4322703295 creator A5084553906 @default.
• W4322703295 date "2015-07-01" @default.
• W4322703295 modified "2023-10-18" @default.
• W4322703295 title "ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients" @default.
• W4322703295 cites W1885425707 @default.
• W4322703295 cites W1964389846 @default.
• W4322703295 cites W1966224341 @default.
• W4322703295 cites W1970082645 @default.
• W4322703295 cites W1974313653 @default.
• W4322703295 cites W1974971484 @default.
• W4322703295 cites W1978196090 @default.
• W4322703295 cites W1985126564 @default.
• W4322703295 cites W1992979605 @default.
• W4322703295 cites W1994296136 @default.
• W4322703295 cites W1994844769 @default.
• W4322703295 cites W1996668651 @default.
• W4322703295 cites W2004345869 @default.
• W4322703295 cites W2007990687 @default.
• W4322703295 cites W2012137498 @default.
• W4322703295 cites W2033283549 @default.
• W4322703295 cites W2047779983 @default.
• W4322703295 cites W2053541821 @default.
• W4322703295 cites W2053991659 @default.
• W4322703295 cites W2058135124 @default.
• W4322703295 cites W2060408251 @default.
• W4322703295 cites W2070727225 @default.
• W4322703295 cites W2079201443 @default.
• W4322703295 cites W2092549386 @default.
• W4322703295 cites W2105011122 @default.
• W4322703295 cites W2112276624 @default.
• W4322703295 cites W2114474071 @default.
• W4322703295 cites W2116576993 @default.
• W4322703295 cites W2123914905 @default.
• W4322703295 cites W2128577473 @default.
• W4322703295 cites W2146666488 @default.
• W4322703295 cites W2159958805 @default.
• W4322703295 cites W2162302094 @default.
• W4322703295 cites W2165847331 @default.
• W4322703295 cites W2165981943 @default.
• W4322703295 cites W4242140596 @default.
• W4322703295 cites W8887711 @default.
• W4322703295 cites W2029593119 @default.
• W4322703295 doi "https://doi.org/10.1093/annonc/mdv173" @default.
• W4322703295 hasPublicationYear "2015" @default.
• W4322703295 type Work @default.
• W4322703295 citedByCount "41" @default.
• W4322703295 countsByYear W43227032952016 @default.
• W4322703295 countsByYear W43227032952017 @default.
• W4322703295 countsByYear W43227032952018 @default.
• W4322703295 countsByYear W43227032952019 @default.
• W4322703295 countsByYear W43227032952020 @default.
• W4322703295 countsByYear W43227032952021 @default.
• W4322703295 countsByYear W43227032952022 @default.
• W4322703295 countsByYear W43227032952023 @default.
• W4322703295 crossrefType "journal-article" @default.
• W4322703295 hasAuthorship W4322703295A5006675365 @default.
• W4322703295 hasAuthorship W4322703295A5008727148 @default.
• W4322703295 hasAuthorship W4322703295A5009371827 @default.
• W4322703295 hasAuthorship W4322703295A5019588141 @default.
• W4322703295 hasAuthorship W4322703295A5020024953 @default.
• W4322703295 hasAuthorship W4322703295A5020487290 @default.
• W4322703295 hasAuthorship W4322703295A5022848420 @default.
• W4322703295 hasAuthorship W4322703295A5024404992 @default.
• W4322703295 hasAuthorship W4322703295A5025761056 @default.
• W4322703295 hasAuthorship W4322703295A5025970784 @default.
• W4322703295 hasAuthorship W4322703295A5027371764 @default.
• W4322703295 hasAuthorship W4322703295A5034604079 @default.
• W4322703295 hasAuthorship W4322703295A5036405779 @default.
• W4322703295 hasAuthorship W4322703295A5038384830 @default.
• W4322703295 hasAuthorship W4322703295A5041410352 @default.
• W4322703295 hasAuthorship W4322703295A5042202815 @default.
• W4322703295 hasAuthorship W4322703295A5043554288 @default.
• W4322703295 hasAuthorship W4322703295A5048784388 @default.

• next